Seok-Chul Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seok-Chul Yang has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Sung Koo Han
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
10 shared publicationsSang-Min Lee
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
9 shared publicationsChul-Gyu Yoo
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
8 shared publicationsYoung Whan Kim
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
7 shared publicationsJae-Joon Yim
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
6 shared publications- Young Whan Kim
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
5 shared publications
Latest Publications
- Open Access
- 1 January 2014
- Published by XMLink in Journal of Korean Medical Science
- Vol. 29 (4) , 507-511
Prognostic Significance of Initial Platelet Counts and Fibrinogen Level in Advanced Non-Small Cell Lung Cancer
Kim KH, et al. J Korean Med Sci. 2014 Apr;29(4):507-511. https://doi.org/10.3346/jkms.2014.29.4.507
- 1 January 2014
- Published by XMLink in Journal of Korean Medical Science
- Vol. 29 (4) , 507-511
Open AccessPrognostic Significance of Initial Platelet Counts and Fibrinogen Level in Advanced Non-Small Cell Lung Cancer
Kim KH, et al. J Korean Med Sci. 2014 Apr;29(4):507-511. https://doi.org/10.3346/jkms.2014.29.4.507
- Open Access
- 1 January 2013
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 54 (5) , 1227-1233
Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities
Kim SY, et al. Yonsei Med J. 2013 Sep;54(5):1227-1233. https://doi.org/10.3349/ymj.2013.54.5.1227
- 1 January 2013
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 54 (5) , 1227-1233
Open AccessTreatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities
Kim SY, et al. Yonsei Med J. 2013 Sep;54(5):1227-1233. https://doi.org/10.3349/ymj.2013.54.5.1227
- Open Access
- 5 July 2012
- Published by Wiley in Thoracic Cancer
- Vol. 4 (2) , 167-173
Prognosis for non-small cell lung cancer patients with brain metastases
Purpose Brain metastasis has a poor prognosis in patients with advanced non-small cell lung cancer (NSCLC). In this study, we evaluated the prognosis of NSCLC patients with brain metastases. Methods We analyzed a total of 313 NSCLC patients with brain metastasis. We compared the prognoses between a group of less than four (group A) and a group of more than four or equal to four (≥4) (group B) brain metastases. Results The median survival time was 334 days (group A, 164 patients, 52.4%) and 234 days (group B, 149 patients, 47.6%). Univariate analysis showed that the number of metastases, age at diagnosis of brain metastasis, smoking history, histologic type, and former stage of primary lung cancer before brain metastasis, had a significant influence. In addition, treatment for primary lung cancer lesions and brain metastasis also affected the overall survival (p < .0001). However, there was no difference in the overall survival between the two groups in the multivariate analysis. Conclusion Our results show that the number of brain metastases, classified by group A (<4) or group B (≥4) did not influence the overall survival of NSCLC patients. However, the overall survival in group A was better than in group B when analyzed, except for local brain treatment modalities in sub-group analysis, suggesting that non-optimized local treatment strategies might cause an unexpected prognosis result in this retrospective study. We suggest that more prospective studies might be needed for the optimal standard treatment for brain metastasis.
- 5 July 2012
- Published by Wiley in Thoracic Cancer
- Vol. 4 (2) , 167-173
Open AccessPrognosis for non-small cell lung cancer patients with brain metastases
Purpose Brain metastasis has a poor prognosis in patients with advanced non-small cell lung cancer (NSCLC). In this study, we evaluated the prognosis of NSCLC patients with brain metastases. Methods We analyzed a total of 313 NSCLC patients with brain metastasis. We compared the prognoses between a group of less than four (group A) and a group of more than four or equal to four (≥4) (group B) brain metastases. Results The median survival time was 334 days (group A, 164 patients, 52.4%) and 234 days (group B, 149 patients, 47.6%). Univariate analysis showed that the number of metastases, age at diagnosis of brain metastasis, smoking history, histologic type, and former stage of primary lung cancer before brain metastasis, had a significant influence. In addition, treatment for primary lung cancer lesions and brain metastasis also affected the overall survival (p < .0001). However, there was no difference in the overall survival between the two groups in the multivariate analysis. Conclusion Our results show that the number of brain metastases, classified by group A (<4) or group B (≥4) did not influence the overall survival of NSCLC patients. However, the overall survival in group A was better than in group B when analyzed, except for local brain treatment modalities in sub-group analysis, suggesting that non-optimized local treatment strategies might cause an unexpected prognosis result in this retrospective study. We suggest that more prospective studies might be needed for the optimal standard treatment for brain metastasis.
- 1 February 2012
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (3_Suppleme) , A22
Abstract A22: Clinical implication of microscopic anthracotic pigment in mediastinal staging of non-small cell lung cancer by endobronchial ultrasound-guided transbronchial needle aspiration
Introduction: Microscopic anthracotic pigment is frequently observed in EBUS-TBNA specimen from non-small cell lung cancer, but the clinical interpretation is not known. The aim of this study was to evaluate the clinical implication of microscopic anthracotic pigment in mediastinal staging of non-small cell lung cancer by EBUS-TBNA. Methods: From May 2010 to July 2011, Consecutive potentially operable non-small cell lung cancer patients who underwent EBUS-TBNA for mediastinal staging were recruited in this retrospective study. Results: Total 133 patients, male were 102 (76.7%). Median age was 68. Squamous cell carcinoma (59, 44.4%) and adenocarcinoma (57, 42.9%) were most common. Clinical stages after EBUS-TBNA were as followed; IA (18.8%), IB (17.3%), IIA (6.0%), IIB (9.0%), IIIA (36.8%), IIIB (12.0%). Total 281 mediastinal lymph nodes were sampled by EBUS-TBNA, station 4R (100, 35.8%) and station 7 (86, 30.8%) were most common sites. Malignant lymph nodes were 100 (35.8%). Microscopic anthracotic pigment was observed in 61 (21.7%) lymph nodes, and among them malignant lymph nodes were only 3 (P<0.001). The lymph nodes with microscopic anthracotic pigment were small (9.0 vs. 10.8 mm, P = 0.001) and low SUV on FDG-PET (5.4 vs. 6.7, P = 0.120). In multivariable analysis, microscopic anthracotic pigment was statistically significant associated with benign lymph node (adjusted OR, 14.3; 95% CI, 3.6–57.3; P<0.001). Conclusion: In potentially operable non-small cell lung cancer patients, microscopic anthracotic pigment in endobronchial ultrasound-guided transbronchial needle aspiration specimen was strongly associated with benign mediastinal lymph node.
- 1 February 2012
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (3_Suppleme) , A22
Abstract A22: Clinical implication of microscopic anthracotic pigment in mediastinal staging of non-small cell lung cancer by endobronchial ultrasound-guided transbronchial needle aspiration
Introduction: Microscopic anthracotic pigment is frequently observed in EBUS-TBNA specimen from non-small cell lung cancer, but the clinical interpretation is not known. The aim of this study was to evaluate the clinical implication of microscopic anthracotic pigment in mediastinal staging of non-small cell lung cancer by EBUS-TBNA. Methods: From May 2010 to July 2011, Consecutive potentially operable non-small cell lung cancer patients who underwent EBUS-TBNA for mediastinal staging were recruited in this retrospective study. Results: Total 133 patients, male were 102 (76.7%). Median age was 68. Squamous cell carcinoma (59, 44.4%) and adenocarcinoma (57, 42.9%) were most common. Clinical stages after EBUS-TBNA were as followed; IA (18.8%), IB (17.3%), IIA (6.0%), IIB (9.0%), IIIA (36.8%), IIIB (12.0%). Total 281 mediastinal lymph nodes were sampled by EBUS-TBNA, station 4R (100, 35.8%) and station 7 (86, 30.8%) were most common sites. Malignant lymph nodes were 100 (35.8%). Microscopic anthracotic pigment was observed in 61 (21.7%) lymph nodes, and among them malignant lymph nodes were only 3 (P<0.001). The lymph nodes with microscopic anthracotic pigment were small (9.0 vs. 10.8 mm, P = 0.001) and low SUV on FDG-PET (5.4 vs. 6.7, P = 0.120). In multivariable analysis, microscopic anthracotic pigment was statistically significant associated with benign lymph node (adjusted OR, 14.3; 95% CI, 3.6–57.3; P<0.001). Conclusion: In potentially operable non-small cell lung cancer patients, microscopic anthracotic pigment in endobronchial ultrasound-guided transbronchial needle aspiration specimen was strongly associated with benign mediastinal lymph node.
- Open Access
- 1 January 2012
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 27 (3) , 311-316
Clinical Features of Patients on Home Oxygen Therapy Due to Chronic Respiratory Failure at One University Hospital
Kim KH, et al. Korean J Intern Med. 2012 Sep;27(3):311-316. http://dx.doi.org/10.3904/kjim.2012.27.3.311
- 1 January 2012
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 27 (3) , 311-316
Open AccessClinical Features of Patients on Home Oxygen Therapy Due to Chronic Respiratory Failure at One University Hospital
Kim KH, et al. Korean J Intern Med. 2012 Sep;27(3):311-316. http://dx.doi.org/10.3904/kjim.2012.27.3.311
- Open Access
- 1 January 2012
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 27 (2) , 189-196
Prognosis in Patients Having Chronic Obstructive Pulmonary Disease with Significant Coronary Artery Lesion Angina
Many studies have investigated angina and its relationship with chronic obstructive pulmonary disease (COPD). However, angina was diagnosed only by noninvasive tests or only by clinical symptoms in most of these studies. The aim of this study was to compare the prognosis, including rate of hospitalization and death from significant coronary artery lesion and nonsignificant coronary artery lesion angina, in patients with COPD. Patients with COPD who underwent coronary angiography (CAG) due to angina were reviewed retrospectively at a tertiary referral hospital. COPD is defined as post-bronchodilator forced expiratory volume in 1 sec/forced vital capacity (FEV(1)/FVC) of < 70%. A significant coronary lesion is defined as at least 50% diameter stenosis of one major epicardial artery in CAG. In total, 113 patients were enrolled. Mean follow-up duration was 39 ± 21 months. Of the patients, 52 (46%) had mild COPD and 48 (42%) had moderate COPD. Sixty-nine (61%) patients had significant stenosis in CAG. The death rate in the follow-up period was 2.21 per 100 patient-years. No significant difference was observed among the all-cause mortality rate, admission rate, or intensive care unit admission rate in patients who had COPD with or without significant coronary artery disease. Pneumonia or acute exacerbation of COPD was the most common cause of admission. In patients having COPD with angina who underwent CAG, no significant difference was observed in mortality or admission events depending on the presence of a significant coronary artery lesion during the 2-year follow-up period.
- 1 January 2012
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 27 (2) , 189-196
Open AccessPrognosis in Patients Having Chronic Obstructive Pulmonary Disease with Significant Coronary Artery Lesion Angina
Many studies have investigated angina and its relationship with chronic obstructive pulmonary disease (COPD). However, angina was diagnosed only by noninvasive tests or only by clinical symptoms in most of these studies. The aim of this study was to compare the prognosis, including rate of hospitalization and death from significant coronary artery lesion and nonsignificant coronary artery lesion angina, in patients with COPD. Patients with COPD who underwent coronary angiography (CAG) due to angina were reviewed retrospectively at a tertiary referral hospital. COPD is defined as post-bronchodilator forced expiratory volume in 1 sec/forced vital capacity (FEV(1)/FVC) of < 70%. A significant coronary lesion is defined as at least 50% diameter stenosis of one major epicardial artery in CAG. In total, 113 patients were enrolled. Mean follow-up duration was 39 ± 21 months. Of the patients, 52 (46%) had mild COPD and 48 (42%) had moderate COPD. Sixty-nine (61%) patients had significant stenosis in CAG. The death rate in the follow-up period was 2.21 per 100 patient-years. No significant difference was observed among the all-cause mortality rate, admission rate, or intensive care unit admission rate in patients who had COPD with or without significant coronary artery disease. Pneumonia or acute exacerbation of COPD was the most common cause of admission. In patients having COPD with angina who underwent CAG, no significant difference was observed in mortality or admission events depending on the presence of a significant coronary artery lesion during the 2-year follow-up period.
- Open Access
- 1 January 2011
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 26 (4) , 421-426
Sound Analysis in anIn VitroEndotracheal Tube Model
Complete endotracheal tube obstruction is a medical emergency, and partial occlusion causes increased breathing rates and failure to wean off mechanical ventilation. Partial occlusion may be underestimated due to the lack of proper detection methods. We tested whether the sound of an endotracheal tube could be used to detect an endotracheal tube obstruction using an in vitro model. An endotracheal tube was connected to a ventilator on one end and a test lung on the other. Sounds were recorded with a microphone located inside the endotracheal tube via a connector. During mechanical ventilation, we changed the endotracheal tube internal diameter from 5.0 to 8.0 mm and different grades of obstruction at different sites were used along the tube. Sound energy was compared among the different conditions. The energy of endotracheal tube sounds was positively correlated with the internal diameter and negatively correlated with the degree of obstruction. The rate of decline in energy differed with obstruction location. When the obstruction was more distal, the rate of decline in endotracheal sound energy was more rapid. Changes in the sound of an endotracheal tube can be used to detect an obstruction. Further studies are needed for clinical application.
- 1 January 2011
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 26 (4) , 421-426
Open AccessSound Analysis in anIn VitroEndotracheal Tube Model
Complete endotracheal tube obstruction is a medical emergency, and partial occlusion causes increased breathing rates and failure to wean off mechanical ventilation. Partial occlusion may be underestimated due to the lack of proper detection methods. We tested whether the sound of an endotracheal tube could be used to detect an endotracheal tube obstruction using an in vitro model. An endotracheal tube was connected to a ventilator on one end and a test lung on the other. Sounds were recorded with a microphone located inside the endotracheal tube via a connector. During mechanical ventilation, we changed the endotracheal tube internal diameter from 5.0 to 8.0 mm and different grades of obstruction at different sites were used along the tube. Sound energy was compared among the different conditions. The energy of endotracheal tube sounds was positively correlated with the internal diameter and negatively correlated with the degree of obstruction. The rate of decline in energy differed with obstruction location. When the obstruction was more distal, the rate of decline in endotracheal sound energy was more rapid. Changes in the sound of an endotracheal tube can be used to detect an obstruction. Further studies are needed for clinical application.
- Open Access
- 1 January 2011
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 26 (2) , 132-134
The Endoscopic Cryotherapy of Lung and Bronchial Tumors: A Systematic Review -Can We Expect a New Era of Cryotherapy in Lung Cancer?
Lee J, et al. Korean J Intern Med. 2011 Jun;26(2):132-134. http://dx.doi.org/10.3904/kjim.2011.26.2.132
- 1 January 2011
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 26 (2) , 132-134
Open AccessThe Endoscopic Cryotherapy of Lung and Bronchial Tumors: A Systematic Review -Can We Expect a New Era of Cryotherapy in Lung Cancer?
Lee J, et al. Korean J Intern Med. 2011 Jun;26(2):132-134. http://dx.doi.org/10.3904/kjim.2011.26.2.132
- 21 July 2010
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 26 (3) , 415-423
The immune modulation of Clara cell-10 in human peripheral monocytes and dendritic cells
Although Clara cell secretory protein (CC-10, CC-16 or uteroglobin, secretoglobin 1A1) has been ascribed anti-inflammatory, immunomodulatory and anti-cancer activity roles in lung diseases including lung cancer, its precise function remains unclear. The objective of the present study was to evaluate the role of CC-10 in the immunomodulation of human monocytes and dendritic cells (DCs). The human lung adenocarcinoma cell line A549, was used to examine PGE2 production after cyclooxygenase (COX) inhibition and adenovirus encoding human CC-10 cDNA (Ad-CC-10) transfection. Type I and II cytokines were measured from peripheral blood mononuclear cells (PBMCs) and DCs which were cultured with tumor supernatant (TSN) or Ad-CC-10 transfected TSN. When PBMCs were cultured with supernatant A549 (tumor supernatant, TSN), the levels of T-cell helper type 1 (Th1) and 2 (Th2) cytokines increased. However, CC-10 inhibited the induction of Th2 cytokines of PBMCs stimulated with TSN. In DCs, TSN inhibited Th1 type cytokines but induced Th2 type. In contrast, TSN treated with either CC-10 or NS398 (COX-2 inhibitor) stimulated Th1 type and inhibited Th2 type without any phenotypic changes. The supernatants generated in the presence of NS-398 or CC-10 prevented tumor-induced inhibition of allogeneic T-cell stimulation. While the level of interleukin (IL)-10 secretion from DC-Ad-CC-10 was decreased, the level of IL-12 secretion was increased by CC-10. Collectively our data suggest that a supernatant of NSCLC causes an imbalance in the immune response of PBMCs and DCs, which is reversed by CC-10. This suggests that CC-10 is a candidate for the development of a new immunotherapy for lung cancer.
- 21 July 2010
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 26 (3) , 415-423
The immune modulation of Clara cell-10 in human peripheral monocytes and dendritic cells
Although Clara cell secretory protein (CC-10, CC-16 or uteroglobin, secretoglobin 1A1) has been ascribed anti-inflammatory, immunomodulatory and anti-cancer activity roles in lung diseases including lung cancer, its precise function remains unclear. The objective of the present study was to evaluate the role of CC-10 in the immunomodulation of human monocytes and dendritic cells (DCs). The human lung adenocarcinoma cell line A549, was used to examine PGE2 production after cyclooxygenase (COX) inhibition and adenovirus encoding human CC-10 cDNA (Ad-CC-10) transfection. Type I and II cytokines were measured from peripheral blood mononuclear cells (PBMCs) and DCs which were cultured with tumor supernatant (TSN) or Ad-CC-10 transfected TSN. When PBMCs were cultured with supernatant A549 (tumor supernatant, TSN), the levels of T-cell helper type 1 (Th1) and 2 (Th2) cytokines increased. However, CC-10 inhibited the induction of Th2 cytokines of PBMCs stimulated with TSN. In DCs, TSN inhibited Th1 type cytokines but induced Th2 type. In contrast, TSN treated with either CC-10 or NS398 (COX-2 inhibitor) stimulated Th1 type and inhibited Th2 type without any phenotypic changes. The supernatants generated in the presence of NS-398 or CC-10 prevented tumor-induced inhibition of allogeneic T-cell stimulation. While the level of interleukin (IL)-10 secretion from DC-Ad-CC-10 was decreased, the level of IL-12 secretion was increased by CC-10. Collectively our data suggest that a supernatant of NSCLC causes an imbalance in the immune response of PBMCs and DCs, which is reversed by CC-10. This suggests that CC-10 is a candidate for the development of a new immunotherapy for lung cancer.
- Open Access
- 1 January 2010
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 25 (4) , 392-398
Influence of Additional Post-Bronchoscopy Visit on Patient Satisfaction after Flexible Bronchoscopy
Many patients undergoing a flexible bronchoscopy (FB) experience anxiety and discomfort during the procedure. We assessed whether an additional patient visit after a FB would improve patient satisfaction. The study patients were randomly assigned to a control and post-visit groups. The physicians who were scheduled to perform the FB visited the study patients. The control group had one visit before the FB and the post-visit group had a before and after FB visit. The post-visit group received additional information and support during the second visit. Twenty-four hours after the FB, the participants completed questionnaires about discomfort and satisfaction with the procedure. The control and post-visit groups included 151 and 153 patients, respectively. The post-visit group reported having more information after the FB than the control group. The additional post-bronchoscopy visit improved the general patient tolerability of the procedure. The willingness to return for another FB was not affected by the post-bronchoscopy patient visit. The post-bronchoscopy visit improved patient satisfaction and general tolerability to the procedure. Subjective patient tolerability with the FB may be improved through a post-bronchoscopy visit by providing more information and emotional support to patients.
- 1 January 2010
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 25 (4) , 392-398
Open AccessInfluence of Additional Post-Bronchoscopy Visit on Patient Satisfaction after Flexible Bronchoscopy
Many patients undergoing a flexible bronchoscopy (FB) experience anxiety and discomfort during the procedure. We assessed whether an additional patient visit after a FB would improve patient satisfaction. The study patients were randomly assigned to a control and post-visit groups. The physicians who were scheduled to perform the FB visited the study patients. The control group had one visit before the FB and the post-visit group had a before and after FB visit. The post-visit group received additional information and support during the second visit. Twenty-four hours after the FB, the participants completed questionnaires about discomfort and satisfaction with the procedure. The control and post-visit groups included 151 and 153 patients, respectively. The post-visit group reported having more information after the FB than the control group. The additional post-bronchoscopy visit improved the general patient tolerability of the procedure. The willingness to return for another FB was not affected by the post-bronchoscopy patient visit. The post-bronchoscopy visit improved patient satisfaction and general tolerability to the procedure. Subjective patient tolerability with the FB may be improved through a post-bronchoscopy visit by providing more information and emotional support to patients.